Ductal Carcinoma
In Situ
405
147. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with duc-
tal carcinoma
in situ
untreated after diagnostic biopsy: results from
the Nurses’ Health Study.
Cancer
2005;103:1778–1784.
148. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of
low-grade ductal carcinoma
in situ
of the breast in women treated by
biopsy only revealed over 30 years of long-term follow-up.
Cancer
2005;103:2481–2484.
149. Goldstein NS, Murphy TM. Intraductal carcinoma associated with in-
vasive carcinoma of the breast: a comparison of the two lesions with
implications for intraductal carcinoma classification systems.
Am J
Clin Pathol
1996;106:312–318.
150. Shoker BS, Sloane JP. DCIS grading schemes and clinical implications.
Histopathology
1999;35:393–400.
151. The Consensus Conference Committee. Consensus Conference on the
classification of ductal carcinoma
in situ
.
Cancer
1997;80:1798–1802.
152. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma
in situ
with basal-
like phenotype: a possible precursor to invasive basal-like breast can-
cer.
Mod Pathol
2006;19:617–621.
153. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification
of breast ductal carcinoma-
in-situ
.
Lancet
1995;345:1154–1157.
154. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for
ductal carcinoma
in situ
of the breast.
Cancer
1996;77:2267–2274.
155. Douglas-Jones AG, Gupta SK, Attanoos RL, et al. A critical appraisal
of six modern classifications of ductal carcinoma
in situ
of the breast
(DCIS): correlation with grade of associated invasive carcinoma.
His-
topathology
1996;29:397–409.
156. Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved
by 23 European pathologists in categorizing ductal carcinoma
in
situ
of the breast using five classifications. European Commis-
sion Working Group on Breast Screening Pathology.
Hum Pathol
1998;29:1056–1062.
157. Scott MA, Lagios MD, Axelsson K, et al. Ductal carcinoma
in situ
of the breast: reproducibility of histological subtype analysis.
Hum
Pathol
1997;28:967–973.
158. Schuh F, Biazús JV, Resetkova E, et al. Reproducibility of three clas-
sification systems of ductal carcinoma
in situ
of the breast using a web-
based survey.
Pathol Res Pract
2010;206:705–711.
159. Pinder SE, Duggan C, Ellis IO, et al. A new pathological system for
grading DCIS with improved prediction of local recurrence: results
from the UKCCCR/ANZ DCIS trial.
Br J Cancer
2010;103:94–100.
160. Balleine RL, Webster LR, Davis S, et al. Molecular grading of
ductal carcinoma
in situ
of the breast.
Clin Cancer Res
2008;14:
8244–8252.
161. Ottinetti A, Sapino A. Morphometric evaluation of microvessels sur-
rounding hyperplastic and neoplastic mammary lesions.
Breast Can-
cer Res Treat
1988;11:241–248.
162. Tamaki K, Sasano H, Maruo Y, et al. Vasohibin-1 as a potential pre-
dictor of aggressive behavior of ductal carcinoma
in situ
of the breast.
Cancer Sci
2010;101:1051–1058.
163. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and
metastasis—correlation in invasive breast cancer.
N Engl J Med
1991;324:1–8.
164. Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and distri-
bution in ductal carcinoma
in situ
of the breast.
J Natl Cancer Inst
1994;86:614–619.
165. Heffelfinger SC, Yassin R, Miller MA, et al. Vascularity of prolifera-
tive breast disease and carcinoma
in situ
correlates with histological
features.
Clin Cancer Res
1996;2:1873–1878.
166. Guidi AJ, Schnitt SJ. Angiogenesis in preinvasive lesions of the breast.
Breast J
1996;2:364–369.
167. Engels K, Fox SB, Whitehouse RM, et al. Distinct angiogenic patterns
are associated with high-grade
in situ
ductal carcinomas of the breast.
J Pathol
1997;181:207–212.
168. Sternlicht MD, Barksy SH. The myoepithelial defense: a host defense
against cancer.
Med Hypotheses
1997;48:37–46.
169. Barsky SH, Nguyen M, Grossman DA, et al. Myoepithelial cells limit
DCIS metastasis by blocking invasion and angiogenesis.
Mod Pathol
1997;10:16A.
170. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as
stromal effectors of human carcinoma progression: therapeutic impli-
cations.
Matrix Biol
1997;15:535–541.
171. Sternlicht MD, Safarians S, Rivera SP, et al. Characterizations of the
extracellular matrix and proteinase inhibitor content of human myo-
epithelial tumors.
Lab Invest
1996;74:781–796.
122. Singh N, Theaker JM. Calcium oxalate crystals (Weddellite) within
the secretions of ductal carcinoma
in situ
—a rare phenomenon.
J Clin
Pathol
1999;52:145–146.
123. Lomme MM, Steinhoff MM. Intraluminal crystalloids in benign
breast ducts.
Breast J
2005;11:510.
124. Mayr NA, Staples JJ, Robinson RA, et al. Morphometric studies in in-
traductal breast carcinoma using computerized image analysis.
Cancer
1991;67:2805–2812.
125. Lindley R, Bulman A, Parsons P, et al. Histologic features predictive of an
increased risk of early local recurrence after treatment of breast cancer by
local tumor excision and radical radiotherapy.
Surgery
1989;105:13–20.
126. Bodis S, Siziopikou KP, Schnitt SJ, et al. Extensive apoptosis in ductal
carcinoma
in situ
of the breast.
Cancer
1996;77:1831–1835.
127. Harn HJ, Shen KL, Yueh KC, et al. Apoptosis occurs more frequently
in intraductal carcinoma than in infiltrating duct carcinoma of hu-
man breast cancer and correlates with altered p53 expression: detected
by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick
end labelling (TUNEL).
Histopathology
1997;31:534–539.
128. Quinn CM, Ostrowski JL, Harkins L, et al. Loss of bcl-2 expression
in ductal carcinoma
in situ
of the breast relates to poor histological
differentiation and to expression of p53 and c-erbB-2 proteins.
Histo-
pathology
1998;33:531–536.
129. Sneige N, Lagios MD, Schwarting R, et al. Interobserver reproducibil-
ity of the Lagios nuclear grading system for ductal carcinoma
in situ
.
Hum Pathol
1999;30:257–262.
130. Muir R, Aitkenhead AC. The healing of intraduct carcinoma of the
mamma.
J Pathol Bacteriol
1934;38:117–127.
131. Davies JD. Hyperelastosis, obliteration and fibrous plaques in major
ducts of the human breast.
J Pathol
1973;110:13–26.
132. Kim HS, Kim GY, Kim YW, et al. Stromal CD10 expression and rela-
tionship to the E-cadherin/beta-catenin complex in breast carcinoma.
Histopathology
2010;56:708–719.
133. Witkiewicz AK, Freydin B, Chervoneva I, et al. Stromal CD10 and
SPARC expression in ductal carcinoma
in situ
(DCIS) patients pre-
dicts disease recurrence.
Cancer Biol Ther
2010;10:391–396.
134. Bagaria SP, Shamonki J, Kinnaird M, et al. The florid subtype of lobu-
lar carcinoma
in situ
: marker of precursor for invasive lobular carci-
noma.
Ann Surg Oncol
2011;18:1845–1851.
135. de Deus Moura R, Wludarski SC, Carvalho FM, et al. Immunohis-
tochemistry applied to the differential diagnosis between ductal and
lobular carcinoma of the breast.
Appl Immunohistochem Mol Morphol
2013;21:1–12.
136. Chan JKC, Ng WF. Sclerosing adenosis cancerized by intraductal car-
cinoma.
Pathology
1987;19:425–428.
137. Eusebi V, Collina G, Bussolati G. Carcinoma
in situ
in sclerosing
adenosis of the breast: an immunocytochemical study.
Semin Diagn
Pathol
1989;6:146–152.
138. Oberman HA, Markey BA. Non-invasive carcinoma of the breast pre-
senting in adenosis.
Mod Pathol
1991;4:31–35.
139. Ichihara S, Aoyama H. Intraductal carcinoma of the breast arising in
sclerosing adenosis. Case report.
Pathol Int
1994;44:722–726.
140. Moritani S, Ichihara S, Hasegawa M, et al. Topographical, morpho-
logical and immunohistochemical characteristics of carcinoma
in situ
of the breast involving sclerosing adenosis. Two distinct topographical
patterns and histological types of carcinoma
in situ
.
Histopathology
2011;58:835–846.
141. Taylor HB, Norris HJ. Epithelial invasion of nerves in benign diseases
of the breast.
Cancer
1967;20:2245–2249.
142. Tsang WYW, Chan JKC. Neural invasion in intraductal carcinoma of
the breast.
Hum Pathol
1992;23:202–204.
143. Bianchi S, Giannotti E, Vanzi E, et al. Radial scar without associated
atypical epithelial proliferation on image-guided 14-gauge needle core
biopsy: analysis of 49 cases from a single-centre and review of the lit-
erature.
Breast
2012;21:159–164.
144. Resetkova E, Edelweiss M, Albarracin CT, et al. Management of radial
sclerosing lesions of the breast diagnosed using percutaneous vac-
uum-assisted core needle biopsy: recommendations for excision based
on seven years of experience at a single institution.
Breast Cancer Res
Treat
2011;127:335–343.
145. Rosen PP. Coexistent lobular carcinoma
in situ
and intraductal carci-
noma in a single lobular-duct unit.
Am J Surg Pathol
1980;4:241–246.
146. Dundar MM, Badve S, Bilgin G, et al. Computerized classification of
intraductal breast lesions using histopathological images.
IEEE Trans
Biomed Eng
2011;58:1977–1984.
